Refine
Has Fulltext
- yes (162)
Is part of the Bibliography
- yes (162)
Year of publication
Document Type
- Journal article (160)
- Doctoral Thesis (1)
- Other (1)
Language
- English (162) (remove)
Keywords
- children (12)
- inflammation (9)
- preterm infants (8)
- bronchopulmonary dysplasia (5)
- immunotherapy (5)
- infection (5)
- influenza (5)
- IL-10 (4)
- Medizin (4)
- Ureaplasma parvum (4)
- autoimmunity (4)
- disease (4)
- juvenile idiopathic arthritis (4)
- macrophages (4)
- monocytes (4)
- pediatric (4)
- treatment (4)
- vaccination (4)
- CRMO (3)
- HBMEC (3)
- NK cells (3)
- T cells (3)
- Th17 (3)
- Ureaplasma urealyticum (3)
- burden (3)
- cells (3)
- cytokines (3)
- immunization (3)
- physical activity (3)
- preterm (3)
- preterm birth (3)
- sepsis (3)
- surfactants (3)
- therapy (3)
- B cell (2)
- B cells (2)
- CCN2 (2)
- CNO (2)
- COVID-19 (2)
- CVID (2)
- Children (2)
- Cystic fibrosis (2)
- DIRA (2)
- Exercise capacity (2)
- Exercise testing (2)
- Germany (2)
- PAPA (2)
- Physical activity (2)
- Pädiatrie (2)
- Rheumatologie (2)
- SARS-CoV-2 (2)
- T cell receptor excision circles (2)
- TLR4 (2)
- TNF-α (2)
- Tregs (2)
- Wilms' tumor (2)
- acute graft-versus-host disease (2)
- animal model (2)
- blood–brain barrier (2)
- bone (2)
- caffeine (2)
- cancer (2)
- case report (2)
- chronic non-bacterial osteomyelitis (2)
- chronic nonbacterial osteomyelitis (2)
- chronic recurrent multifocal osteomyelitis (2)
- cord blood (2)
- cystic fibrosis (2)
- deficiency (2)
- efficacy (2)
- endothelial cells (2)
- epithelial cells (2)
- expression (2)
- flow cytometry (2)
- gene (2)
- glucocorticoids (2)
- hospitalizations (2)
- hypophosphatasia (2)
- hypoxia (2)
- immunoblotting (2)
- in vitro (2)
- innate immunity (2)
- leukemia (2)
- medicine (2)
- meningitis (2)
- messenger RNA (2)
- mouse models (2)
- neonate (2)
- neonates (2)
- nervous system (2)
- neuroinflammation (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- pediatrics (2)
- preterm infant (2)
- regulatory T cells (2)
- sustained inflammation (2)
- transplantation (2)
- treatment guidelines (2)
- tumor (2)
- tumor microenvironment (2)
- ACP5 (1)
- AD-AID (1)
- AICDA (1)
- AID-ΔE4a (1)
- ALPL (1)
- ARDS (1)
- Abatacept (1)
- Accelerometry (1)
- Age (1)
- Allogeneic stem cell transplantation (1)
- Anti-TNF-alpha agents (1)
- Antibody (1)
- Apoptosis (1)
- Aspergillus (1)
- Aspergillus fumigatus (1)
- Autoinflammation (1)
- B cell deficiency (1)
- B cell maturation (1)
- B cell receptor (1)
- B-cell (1)
- B4GALT7 gene (1)
- BPD (1)
- Bevacizumab (1)
- Big picture (1)
- Blood stream infection (1)
- Body composition (1)
- Bone health (1)
- Bronchopulmonary dysplasia (1)
- C-reactive protein (1)
- C5a (1)
- C5aR1 (1)
- CAR-T cells (1)
- CD105 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD62L (1)
- CD8 (1)
- CDR3 sequences (1)
- CMV (1)
- CNS cancer (1)
- CNS integrity (1)
- CTGF (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- Cardiovascular disease (1)
- Caspase (1)
- Central venous access (1)
- Childhood cancer survivors (1)
- Chimeric Antigen Receptor T cells (1)
- Chorioamnionitis (1)
- Cigarette smoking (1)
- Coverage (1)
- Cushing (1)
- Cytokine GM-CSF (1)
- DC vaccination (1)
- DNA methylation (1)
- DNA-binding proteins (1)
- DTPa-HBV-IPV/Hib (1)
- DWI (1)
- Dendra2 (1)
- Deutschland (1)
- Disease severity (1)
- Diseases (1)
- Dixon (1)
- E. coli (1)
- ECORN-CF Projekt (1)
- ESPED (1)
- EU-RHAB registry (1)
- England (1)
- Epidemiology (1)
- Epidural Analgesia (1)
- Erratum (1)
- Escherichia coli (1)
- European Society for Immunodeficiencies (ESID) (1)
- European experience (1)
- Exacerbation (1)
- Exercise intervention (1)
- Extraocular eye muscles (1)
- FADS (1)
- Foxp3 (1)
- GLDN variant (1)
- Gamma (1)
- Gastroenteritis (1)
- German PID-NET registry (1)
- Glut1DS (1)
- Graft-versus-host disease (1)
- Grippe (1)
- H441 (1)
- HLA-G gene (1)
- HPP (1)
- HRQOL (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- Hemagglutination inhibition (1)
- Hickman catheter (1)
- Hospitalisation (1)
- Hospitalization (1)
- ICD-10 (1)
- IL-1 beta (1)
- IL-1 blockade (1)
- IL-10 expression (1)
- IL-12B (1)
- IL-12p40 (1)
- IL-17A-inhibition (1)
- IL12B (1)
- IMR-90 (1)
- IgD (1)
- IgG (1)
- IgG substitution therapy (1)
- IgM (1)
- Immunogenicity (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Impfplan (1)
- Impfung (1)
- Incidence (1)
- Incontinentia pigmenti (1)
- Infectious disease (1)
- Influenza (1)
- Influenza vaccination (1)
- JIA (1)
- Jugend (1)
- Juvenile idiopathic arthritis (1)
- Keuchhusten (1)
- Kindergarten (1)
- LCCS11 (1)
- LND (1)
- LNE (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Late-effects (1)
- Longitudinal analysis (1)
- Lung disease, (1)
- Lymphocytes (1)
- M1/M2 macrophages (1)
- MDSC (1)
- MHC I (1)
- MHC II (1)
- MRI spectroscopy (1)
- MTL30 (1)
- Majeed (1)
- Majeed-Syndrome (1)
- Masern (1)
- Mechanisms (1)
- Medicine (1)
- Meningitis (1)
- Metastases (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Mucopolysaccharidosis IIIa (1)
- Mumps (1)
- Muscle function (1)
- Muscle power (1)
- NADPH oxidase (1)
- NBAS (1)
- NK cell deficiency (1)
- Naive T cells (1)
- Necrotizing enterocolitis (1)
- Neuroinflammation (1)
- OPT (1)
- Oxygen uptake (1)
- P67(PHOX) (1)
- PAPA syndrome (1)
- PET/CT (1)
- PID prevalence (1)
- PLAG1 rearrangement (1)
- POEM (1)
- PU.1 (1)
- Paediatric (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Pediatric (1)
- Pediatric malignancy (1)
- Peyer's patch (1)
- Phosphorylation (1)
- Physical fitness (1)
- Pneumococcal vaccination (1)
- Port (1)
- Preterm birth (1)
- Prevalence (1)
- Quality of life (1)
- Questionnaire (1)
- RHO (1)
- RNA isolation (1)
- RSV-A ON1 (1)
- RTPS1 (1)
- RTPS2 (1)
- Randomized controlled trial (1)
- Regulatory T cells (1)
- Regulatory T-cells (1)
- Remifentanil (1)
- Respiratory tract infection (1)
- Retinopathy (1)
- Rhabdomyosarcoma (1)
- Risk (1)
- Rituximab (1)
- Rotavirus (1)
- Röteln (1)
- SB332235 (1)
- SIRP-alpha (1)
- SMAD signaling (1)
- Safety (1)
- Schnitzler syndrome (1)
- Staphylococcus aureus (1)
- Streptococcus pneumoniae (1)
- Streptococcus pyogenes (1)
- Surveillance (1)
- T and NK development (1)
- T cell migration (1)
- T cell plasticity (1)
- T lymphocytes (1)
- T-cell (1)
- T-cell responses (1)
- TB (1)
- TCR diversity (1)
- TH1-induced senescence (1)
- TH17 cells (1)
- TLR agonists (1)
- TMJ (1)
- TNAP (1)
- TREC (1)
- TRECs (1)
- T\(_H\)17 cells (1)
- Telomere (1)
- Telomeres (1)
- Th9 (1)
- Thrombosis (1)
- Tocilizumab (1)
- Toll-like receptor signaling (1)
- Treg (1)
- Trousseau's syndrome (1)
- United States (1)
- Universal mass vaccination (1)
- Ureaplasma (1)
- Ureaplasma species (1)
- VEGF (1)
- VIBE (1)
- VLBW (1)
- Vaccination (1)
- Vaccine (1)
- Varicella (1)
- Varizellen-Virus (1)
- Viruses (1)
- Vorschulkind (1)
- Wechsler intelligence scale (WISC-IV) (1)
- Wilm's tumor (1)
- achalasia (1)
- activity (1)
- acute (1)
- acute ITP (1)
- acute lymphocytic leukaemia (1)
- adenocarcinoma of the lung (1)
- adolescents (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical carcinoma (1)
- adults (1)
- adverse pulmonary outcomes (1)
- aging (1)
- airway remodeling (1)
- alkaline phosphatase (1)
- allogeneic stem cell transplantation (1)
- alloreactive T cells (1)
- alveolar epithelium in vitro model, claudin-1, claudin-3, claudin-4, claudin-5 (1)
- amniotic infection (1)
- anaplastic medulloblastoma (1)
- antenatal inflammation (1)
- anti inflammation (1)
- anti-tumor agents (1)
- antibacterial activity (1)
- antibiotic resistance (1)
- antibiotic therapy (1)
- antibiotic use (1)
- antibody (1)
- antidepressants (1)
- antimicrobial activity (1)
- antimicrobial immunity (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antinuclear antibodies (1)
- anuria (1)
- anxiety disorders (1)
- apoptosis (1)
- arterial hypotension (1)
- arthrogryposis (1)
- asfotase alfa (1)
- asymmetry (1)
- atypical chemokine receptor 3 (1)
- atypical teratoid rhabdoid tumors (1)
- autoimmune encephalitis (1)
- autoinflammation (1)
- autologous stem cell transplantation (1)
- autophagy (1)
- axon guidance genes (1)
- axonopathy (1)
- barrier (1)
- beta-D-glucan (1)
- biomarker (1)
- bioreactor culture (1)
- bisphosphonate treatment (1)
- blastocysts (1)
- bleding disorders other than hemophilia (1)
- bleeding score (1)
- bone autoinflammation (1)
- bovine lactoferricin (1)
- brain development (1)
- brain tumor (1)
- breast cancer (1)
- breastfeeding (1)
- breath-hold (1)
- bronchopulmonary dysplasia (BPD) (1)
- bullae (1)
- caffein (1)
- cancer microenvironment (1)
- cancer stem cells (1)
- cancer vaccines (1)
- cancer-targeted IL-12 (1)
- cardiogenic (1)
- cardiovascular risk (1)
- cell therapy (1)
- cellular signalling networks (1)
- central venous catheter (1)
- cerebral calcification (1)
- childhood leukemia (1)
- chorioamnionitis (1)
- chronic pulmonary insufficiency of prematurity (1)
- cidofovir (1)
- clinical application (1)
- clinical trial (1)
- cloning (1)
- coagulopathy (1)
- cognitive profile (1)
- combinatorial drug predictions (1)
- combined therapy (1)
- common variable immunodeficiency (1)
- complication (1)
- computer modelling (1)
- condyle pathomorphology (1)
- congenital dyserythropoietic anemia (1)
- connective tissue disorder (1)
- continuous positive airway pressure (CPAP) (1)
- corticosteroids (1)
- coverage (1)
- craniosynostosis (1)
- cytokine (1)
- cytoskeleton (1)
- cytotoxic effect (1)
- dendritic cells (1)
- depression (1)
- derivatives (1)
- desmoplastic small round cell tumor (1)
- dexamethasone (1)
- diagnosis (1)
- diagnostic delay (1)
- diaphragmatic hypomotility (1)
- differentiation (1)
- diffusion-weighted MRI (1)
- disease severity (1)
- double negative B cells (1)
- drug therapy (1)
- dry lung syndrome (1)
- dual guidance (1)
- dysplasia (1)
- early onset sepsis (1)
- effector cells (1)
- endogenous pulmonary stem cells (1)
- endoglin (1)
- epidemiology (1)
- epitope mapping (1)
- essential tremor (1)
- exercise intervention (1)
- exercise testing (1)
- exercise tolerance (1)
- exposure (1)
- extracellular vesicles (1)
- extracorporeal membrane oxygenation (1)
- extracranial malignant rhabdoid tumor (1)
- factor XIII deficiency (1)
- familial hemophagocytic lymphohistiocytosis (1)
- fetal lung (1)
- fibrosis (1)
- follow up (1)
- forearm (1)
- fungal infection (1)
- gadoxetic acid (1)
- galactomannan (1)
- galectin-1 (1)
- galectin-3 (1)
- galectin-9 (1)
- gender gap (1)
- gene expression (1)
- general practitioner (1)
- genetics (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- germline mutation (1)
- glioblastoma multiforme (1)
- gliomedin (1)
- graft-versus host (1)
- group 3 (1)
- health (1)
- healthcare costs (1)
- healthy children (1)
- hematology (1)
- hemorrhagic (1)
- hemostasis and thrombosis (1)
- henoch-schönlein purpura (1)
- hexavalent vaccine (1)
- hospital exemption (1)
- hospitalization (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human monocytes (1)
- humanized mice (1)
- humans (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hyperfibrinolysis (1)
- hyperoxia (1)
- hypertrophic osteodystrophy (1)
- hypogammaglobulinemia (1)
- imaging (1)
- immaturity (1)
- immune reconstitution (1)
- immune response (1)
- immunocytokine (1)
- immunodeficiency (1)
- immunoglobulin repertoire (1)
- immunoglobulins (1)
- immunology (1)
- immunomodulation (1)
- immunosenescence (1)
- immunotherapies (1)
- in vivo cell tracking (1)
- inattention/hyperactivity (1)
- inborn error of immunity (1)
- infection spread (1)
- infections: pneumonia (1)
- infectious diseases management (1)
- inflammatory diseases (1)
- influenza A virus (1)
- influenza vaccination (1)
- inhibit (1)
- innate immune response (1)
- innate immunity training (1)
- intelligence (1)
- intensive care (1)
- interferon gamma (1)
- interleukin-8 (1)
- interleukin-9 (1)
- interventional radiology (1)
- intravenous immunoglobulins (1)
- invasiveness (1)
- ischemia/reperfusion injury (1)
- juvenile progressive respiratory insufficiency (1)
- ketogenic dietary therapy (KDT) (1)
- knowledge (1)
- lactoferricin B (1)
- late onset sepsis (1)
- lethality rate (1)
- lines (1)
- lipoblastoma (1)
- liquid biopsy (1)
- live-attenuated influenza vaccine (1)
- long-term outcome (1)
- loop region (1)
- luciferase (1)
- lung (1)
- lung injury (1)
- lung remodeling (1)
- lung transplantation (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lymphocyte homing (1)
- lymphocytes (1)
- lymphoplasmacellular osteomyelitis (1)
- maintenance therapy (1)
- malignant glioma (1)
- maternal critical care (1)
- measles (1)
- mechanisms (1)
- medulloblastoma (1)
- mesenchymal stromal cell (1)
- meta-analysis (1)
- metabolic reprogramming (1)
- metabolic syndrome (1)
- metabolism (1)
- metanalysis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- mhc molecules (1)
- mice (1)
- microbiome (1)
- middle cerebral artery occlusion (1)
- migration (1)
- mineralization (1)
- mitophagy (1)
- modular tumor tissue models (1)
- monocyte subsets (1)
- monocyte-derived DC (1)
- movement disorder (1)
- movement disorders (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiresistance (1)
- multi‑center cohort study (1)
- murine model (1)
- mutation (1)
- mutational targeting (1)
- myeloid (1)
- naive T cells (1)
- near infrared spectroscopy (1)
- neoepitope-derived peptides (1)
- neonatal immunology (1)
- neonatal meningitis (1)
- neonatal morbidity (1)
- neonatal outcome (1)
- neonatal renal failure (1)
- neuroblastoma (1)
- neuroblastoma – diagnosis (1)
- neurocognitive outcome (1)
- neutrophils (1)
- newly diagnosed ITP (1)
- non-invasive respiratory support (1)
- non-invasive ventilation (1)
- non-responder (1)
- nutrition education (1)
- observational (1)
- obstetrics (1)
- oligohydramnios sequence (1)
- orthodenticle homeobox 2 (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- outcome (1)
- outpatient (1)
- p.R245H (1)
- p.S298P (1)
- paediatric cancer (1)
- pancreatic carcinoma (1)
- panic disorder (1)
- parapneumonic pleural effusion (1)
- partially-supervised (1)
- participation in clinical trials (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pediatric immune thrombocytopenia (1)
- pediatric patients (1)
- pediatric stem cell transplantation (1)
- pediatrician (1)
- perioperative bleeding (1)
- peroral endoscopic myotomy (1)
- persistence (1)
- phosphorylation (1)
- photoconversion (1)
- platelet disorders (1)
- pleural empyema (1)
- pleural fluid (1)
- poly(I:C) (1)
- polymicrobial infection (1)
- polymorphism (1)
- population coverage (1)
- post-pandemic (1)
- potter sequence (1)
- prediction (1)
- pregnancy (1)
- premature (1)
- prematurity (1)
- preschool children (1)
- preterm children (1)
- prevention program (1)
- primary antibody deficiency (1)
- primary care (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (PID) (1)
- primary schoolchildren (1)
- primary vaccination (1)
- probiotic prophylaxis (1)
- prognostic factors (1)
- prognostic marker (1)
- promoter (1)
- prophylaxis (1)
- prostaglandin E2 (1)
- protein expression (1)
- quality of life (1)
- quality-control (1)
- radiotherapy (1)
- randomised controlled trial (1)
- rare bone disease (1)
- rare diseases (1)
- rat (1)
- re-aim framework (1)
- real-time PCR (1)
- recommendations (1)
- refractory aGvHD (1)
- region (1)
- regional cerebral oxygenation saturation (1)
- registry for primary immunodeficiency (1)
- regulatory dendritic cells (1)
- renal tubular dysgenesis (1)
- reoxygenation (1)
- resident memory T cells (1)
- resistant acid phosphatase (1)
- resolution (1)
- respiratory distress (1)
- respiratory distress syndrome (RDS) (1)
- respiratory-distress-syndrome (1)
- retroperitoneal tumor (1)
- review (1)
- rhabdomyosarcoma (1)
- rheumatoid arthritis (1)
- rickets (1)
- risk factors (1)
- safety (1)
- scoliosis (1)
- seasonal influenza (1)
- semaphorin (1)
- septic (1)
- serum (1)
- shock (1)
- shuttle run test (1)
- skin-to-skin contact (1)
- soft tissue sarcoma (1)
- soluble endoglin (1)
- somatic hypermutation (1)
- spectrum (1)
- speech motor impairment (1)
- spondylodysplastic Ehlers-Danlos syndrome (1)
- spondyloenchondrodysplasia (1)
- standard (1)
- stem cells (1)
- stem/progenitor cells (1)
- steroid-resistant aGvHD (1)
- strength and difficulties (1)
- streptococci (1)
- stroke (1)
- suppression (1)
- suppressive function (1)
- surfactant (1)
- surfactant protein-A (1)
- surveillance (1)
- survey (1)
- sustained lung inflation (SLI) (1)
- sweat osmolality (1)
- sweat secretion rate (1)
- synovial fluid (1)
- synovitis (1)
- synthetic peptides (1)
- synthetic surfactant (1)
- systematic review (1)
- systemic lupus erythematosus (1)
- systemic sclerosis (1)
- teeth (1)
- telomere length (1)
- telomeres (1)
- therapeutic vaccines (1)
- therapy response (1)
- thermoregulation (1)
- thymectomy (1)
- thymus (1)
- tight junctions (1)
- tool (1)
- totally implantable venous access port (1)
- trained immunity (1)
- transcription factors (1)
- transmission (1)
- transmission model (1)
- trap (1)
- tremor (1)
- tumor-infiltrating lymphocytes (1)
- tumor-specific CD8+ T cells (1)
- tumors (1)
- tumour immunology (1)
- type I interferonopathy (1)
- vaccination program (1)
- vaccine (1)
- varicella (1)
- varicella-zoster virus immunosuppression (1)
- vascular access (1)
- vascular disturbances (1)
- vascular homeostasis (1)
- vasculitis (1)
- vasopressin (1)
- vesicle trafficking (1)
- viral (1)
- volume (1)
- young children (1)
- zebrafish (1)
Institute
- Kinderklinik und Poliklinik (162) (remove)
Sonstige beteiligte Institutionen
- Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria (1)
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) (1)
EU-Project number / Contract (GA) number
- 229289 (1)
- 241778 (1)
- 278514 (1)
- 609,020 (1)
- HEALTH-F2-2009-241778 (1)
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors
(2021)
Background
Atypical teratoid/rhabdoid tumors (AT/RT) are highly aggressive CNS tumors of infancy and early childhood. Hallmark is the surprisingly simple genome with inactivating mutations or deletions in the SMARCB1 gene as the oncogenic driver. Nevertheless, AT/RTs are infiltrated by immune cells and even clonally expanded T cells. However, it is unclear which epitopes T cells might recognize on AT/RT cells.
Methods
Here, we report a comprehensive mass spectrometry (MS)-based analysis of naturally presented human leukocyte antigen (HLA) class I and class II ligands on 23 AT/RTs. MS data were validated by matching with a human proteome dataset and exclusion of peptides that are part of the human benignome. Cryptic peptide ligands were identified using Peptide-PRISM.
Results
Comparative HLA ligandome analysis of the HLA ligandome revealed 55 class I and 139 class II tumor-exclusive peptides. No peptide originated from the SMARCB1 region. In addition, 61 HLA class I tumor-exclusive peptide sequences derived from non-canonically translated proteins. Combination of peptides from natural and cryptic class I and class II origin gave optimal representation of tumor cell compartments. Substantial overlap existed with the cryptic immunopeptidome of glioblastomas, but no concordance was found with extracranial tumors. More than 80% of AT/RT exclusive peptides were able to successfully prime CD8+ T cells, whereas naturally occurring memory responses in AT/RT patients could only be detected for class II epitopes. Interestingly, >50% of AT/RT exclusive class II ligands were also recognized by T cells from glioblastoma patients but not from healthy donors.
Conclusions
These findings highlight that AT/RTs, potentially paradigmatic for other pediatric tumors with a low mutational load, present a variety of highly immunogenic HLA class I and class II peptides from canonical as well as non-canonical protein sources. Inclusion of such cryptic peptides into therapeutic vaccines would enable an optimized mapping of the tumor cell surface, thereby reducing the likelihood of immune evasion.
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in early childhood. Underlying pathomechanisms of elevated pulmonary morbidity in later infancy are largely unknown. We found that RSV-infected H441 cells showed increased mRNA expression of connective tissue growth factor (CTGF), a key factor in airway remodeling. Additional dexamethasone treatment led to further elevated mRNA levels, indicating additive effects. Caffeine treatment prevented RSV-mediated increase in CTGF mRNA. RSV may be involved in airway remodeling processes by increasing CTGF mRNA expression. Caffeine might abrogate these negative effects and thereby help to restore lung homeostasis.
Background
Infants with history of prematurity (<37 weeks gestation) and low birth weight (LBW, <2500 g) are at high risk of infection due to functional immaturity of normal physical and immunological defense mechanisms. Despite current recommendations that infants with history of prematurity/LBW should receive routine immunization according to the same schedule and chronological age as full-term infants, immunization is often delayed.
Methods
Here we summarize 10 clinical studies and 15 years of post-marketing safety surveillance of GSK’s hexavalent vaccine (DTPa-HBV-IPV/Hib), a combined diphtheria-tetanus-acellular-pertussis-hepatitis-B-inactivated-poliovirus-Haemophilus influenzae-type-b (Hib) conjugate vaccine, when administered alone, or co-administered with pneumococcal conjugate, rotavirus, and meningococcal vaccines and respiratory syncytial virus IgG to infants with history of prematurity/LBW in clinical trials.
Results
At least 92.5% of infants with history of prematurity/LBW as young as 24 weeks gestation in clinical studies were seropositive to all vaccine antigens after 3-dose primary vaccination with GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine, with robust immune responses to booster vaccination. Seropositivity rates and antibody concentrations to hepatitis B and Hib appeared lower in infants with history of prematurity/LBW than term infants. Between 13–30% of medically stable infants with history of prematurity developed apnea after vaccination with GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine; usually after dose 1. The occurrence of post-immunization cardiorespiratory events appears to be influenced by the severity of any underlying neonatal condition. Most cardiorespiratory events resolve spontaneously or require minimal intervention. GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine was well tolerated in co-administration regimens.
Conclusion
GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine alone or co-administered with other pediatric vaccines has a clinically acceptable safety and immunogenicity profile when used in infants with history of prematurity/LBW for primary and booster vaccination. Additional studies are needed in very premature and very LBW infants. However, currently available data support using GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine to immunize infants with history of prematurity/LBW according to chronological age.
Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma
(2018)
Medulloblastoma (MB) is the most common malignant primary pediatric brain cancer. Among the most aggressive subtypes, Group 3 and Group 4 originate from stem/progenitor cells, frequently metastasize, and often display the worst prognosis, yet we know the least about the molecular mechanisms driving their progression. Here, we show that the transcription factor orthodenticle homeobox 2 (OTX2) promotes self-renewal while inhibiting differentiation in vitro and increases tumor initiation from MB stem/progenitor cells in vivo. To determine how OTX2 contributes to these processes, we employed complementary bioinformatic approaches to characterize the OTX2 regulatory network and identified novel relationships between OTX2 and genes associated with neuronal differentiation and axon guidance signaling in Group 3 and Group 4 MB stem/progenitor cells. In particular, OTX2 levels were negatively correlated with semaphorin (SEMA) signaling, as expression of 9 SEMA pathway genes is upregulated following OTX2 knockdown with some being potential direct OTX2 targets. Importantly, this negative correlation was also observed in patient samples, with lower expression of SEMA4D associated with poor outcome specifically in Group 4 tumors. Functional proof-of-principle studies demonstrated that increased levels of select SEMA pathway genes are associated with decreased self-renewal and growth in vitro and in vivo and that RHO signaling, known to mediate the effects of SEMA genes, is contributing to the OTX2 KD phenotype. Our study provides mechanistic insight into the networks controlled by OTX2 in MB stem/progenitor cells and reveals novel roles for axon guidance genes and their downstream effectors as putative tumor suppressors in MB.
Objectives
Parapneumonic pleural effusions/empyema (PPE/PE) are severe complications of community-acquired pneumonia. We investigated the bacterial aetiology and incidence of paediatric PPE/PE in Germany after the introduction of universal pneumococcal conjugate vaccine (PCV) immunization for infants.
Methods
Children <18 years of age hospitalized with pneumonia-associated PPE/PE necessitating pleural drainage or persisting >7 days were reported to the German Surveillance Unit for Rare Diseases in Childhood between October 2010 and June 2017. All bacteria detected in blood or pleural fluid (by culture/PCR) were included, with serotyping for Streptococcus pneumoniae.
Results
The median age of all 1447 PPE/PE patients was 5 years (interquartile range 3–10). In 488 of the 1447 children with PPE/PE (34%), 541 bacteria (>40 species) were detected. Aerobic gram-positive cocci accounted for 469 of 541 bacteria detected (87%); these were most frequently Streptococcus pneumoniae (41%), Streptococcus pyogenes (19%) and Staphylococcus aureus (6%). Serotype 3 accounted for 45% of 78 serotyped S. pneumoniae strains. Annual PPE/PE incidence varied between 14 (95%CI 12–16) and 18 (95%CI 16–21) PPE/PE per million children. Incidence of S. pneumoniae PPE/PE decreased from 3.5 (95%CI 2.5–4.6) per million children in 2010/11 to 1.5 (95%CI 0.9–2.4) in 2013/14 (p 0.002), followed by a re-increase to 2.2 (95%CI 1.5–3.2) by 2016/17 (p 0.205).
Conclusions
In the era of widespread PCV immunization, cases of paediatric PPE/PE were still caused mainly by S. pneumoniae and, increasingly, by S. pyogenes. The re-increase in the incidence of PPE/PE overall and in S. pneumoniae-associated PPE/PE indicates ongoing changes in the bacterial aetiology and requires further surveillance.
The regulation of immune cell migration throughout the body is essential to warrant immunosurveillance and to maintain immune homeostasis. Marking and tracking of these cells has proven important to study mechanisms of immune cell trafficking and cell interaction in vivo. Photoconversion is a well-suited technique for intravital application because it enables contactless time- and location-specific marking of cells in the tissue without surgically manipulating the microenvironment of the cells in question. However, in dividing cells the converted fluorescent protein may decline quickly. Here, we provide a detailed description of the photoconversion technique and its applicability to tracking highly proliferating T cells from the priming site of T cell activation to peripheral target organs of effector function in a preclinical model. Dendra2+ T cells were photoconverted in the Peyer’s patches during the initiation phase of acute graft-versus-host disease (GvHD) and tracked through the mesenteric lymph nodes and the peripheral blood to the small intestine with flow cytometry and intravital two-photon microscopy. Photoconverted alloreactive T cells preserved the full proliferative capacity, homing, and migration of alloreactive T cells in the intestinal lamina propria. We conclusively proved that photoconversion of highly proliferative alloreactive T cells in the Peyer’s patches is an effective tool to study trafficking of alloreactive T cells under physiologic conditions and to GvHD target tissues. This technique can also be applied to the study of immune cell tracking under inflammatory and non-inflammatory conditions.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Purpose
Biallelic pathogenic NBAS variants manifest as a multisystem disorder with heterogeneous clinical phenotypes such as recurrent acute liver failure, growth retardation, and susceptibility to infections. This study explores how NBAS-associated disease affects cells of the innate and adaptive immune system.
Methods
Clinical and laboratory parameters were combined with functional multi-parametric immunophenotyping methods in fifteen NBAS-deficient patients to discover possible alterations in their immune system.
Results
Our study revealed reduced absolute numbers of mature CD56dim natural killer (NK) cells. Notably, the residual NK cell population in NBAS-deficient patients exerted a lower potential for activation and degranulation in response to K562 target cells, suggesting an NK cell–intrinsic role for NBAS in the release of cytotoxic granules. NBAS-deficient NK cell activation and degranulation was normalized upon pre-activation by IL-2 in vitro, suggesting that functional impairment was reversible. In addition, we observed a reduced number of naïve B cells in the peripheral blood associated with hypogammaglobulinemia.
Conclusion
In summary, we demonstrate that pathogenic biallelic variants in NBAS are associated with dysfunctional NK cells as well as impaired adaptive humoral immunity.
B cell maturation and immunoglobulin (Ig) repertoire selection are governed by expression of a functional B cell receptor (BCR). Naïve B cells co-express their BCR as IgM and IgD isotype. However, the role of the additionally expressed IgD on naïve B cells is not known. Here we assessed the impact of IgD on naïve B cell maturation and Ig repertoire selection in 8 individuals from 3 different families with heterozygous loss-of-function or loss-of expression mutations in IGHD. Although naïve B cells from these individuals expressed IgM on their surface, the IGHD variant in heterozygous state entailed a chimeric situation by allelic exclusion with almost half of the naïve B cell population lacking surface IgD expression. Flow cytometric analyses revealed a distinct phenotype of IgD-negative naïve B cells with decreased expression of CD19, CD20 and CD21 as well as lower BAFF-R and integrin-β7 expression. IgD-negative B cells were less responsive in vitro after engaging the IgM-BCR, TLR7/9 or CD40 pathway. Additionally, a selective disadvantage of IgD-negative B cells within the T2 transitional and mature naïve B cell compartment as well as reduced frequencies of IgMlo/- B cells within the mature naïve B cell compartment lacking IgD were evident. RNA-Ig-seq of bulk sorted B cell populations showed an altered selection of distinct VH segments in the IgD-negative mature naïve B cell population. We conclude that IgD expression on human naïve B cells is redundant for generation of naïve B cells in general, but further shapes the naive B cell compartment starting from T2 transitional B cells. Our observations suggest an unexpected role of IgD expression to be critical for selection of distinct Ig VH segments into the pre-immune Ig repertoire and for the survival of IgMlo/- naïve B cells known to be enriched in poly-/autoreactive B cell clones.